ZBTB45: A Non-Coding RNA-Binding Protein as A Potential Drug Target and Biomarker

Target Name: ZBTB45

NCBI ID: G84878

ZBTB45

ZBTB45: A Non-Coding RNA-Binding Protein as A Potential Drug Target and Biomarker

ZBTB45, also known as zinc finger protein 499, is a protein that is expressed in a wide range of tissues in the human body. It is a type of non-coding RNA-binding protein, which means it interacts with RNA molecules to regulate their translated into proteins. ZBTB45 is a protein that has been identified as a potential drug target and biomarker for a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The ZBTB45 protein is composed of 254 amino acid residues and has a calculated molecular mass of 33.1 kDa. It is expressed in a variety of tissues, including muscle, heart, brain, liver, and kidney. ZBTB45 is predominantly expressed in the brain, and it is also expressed in the liver, spleen, and skeletal muscle. It is highly expressed in the brain, with levels ranging from 10 to 100 mg/g of muscle protein.

ZBTB45 is a protein that has been shown to play a role in a number of important cellular processes. It is involved in the regulation of gene expression, cell signaling, and cell division. ZBTB45 has been shown to interact with a variety of transcription factors, including NF-kappa-B, AP-1, and STAT3. It is also known to play a role in the regulation of cellular transport processes, including the transport of nutrients and oxygen into cells and the transport of waste products out of cells.

In addition to its role in cellular signaling, ZBTB45 is also a potential drug target. Researchers have identified several potential drugs that can interact with ZBTB45 and are currently studying the potential efficacy of these drugs in a variety of diseases. One of the drugs that is being studied is QXMD2, which is a small molecule that can interact with ZBTB45 and is being investigated as a potential treatment for neurodegenerative diseases.

Another potential drug that is being studied for its ability to interact with ZBTB45 is U012649, which is an oral small molecule that can interact with ZBTB45 and is being investigated as a potential treatment for multiple sclerosis. In addition to U012649, researchers are also studying the potential efficacy of several other drugs, including inhibitors of protein-protein interactions, small molecules that can modulate ZBTB45 expression, and small molecules that can inhibit ZBTB45 function.

ZBTB45 is also being studied as a potential biomarker for a number of diseases. Researchers have shown that ZBTB45 levels are often elevated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that ZBTB45 may be a useful biomarker for these diseases. In addition, ZBTB45 levels have been shown to be elevated in a variety of biological samples, including blood, urine, and tissue samples. This suggests that ZBTB45 may be a useful biomarker for a wide range of biological processes.

Overall, ZBTB45 is a protein that has been identified as a potential drug target and biomarker for a number of diseases. Further research is needed to fully understand the role of ZBTB45 in cellular signaling and the potential utility of ZBTB45 as a drug or biomarker.

Protein Name: Zinc Finger And BTB Domain Containing 45

Functions: May be involved in transcriptional regulation (Probable). In the central nervous system, may play a role in glial cell differentiation (By similarity)

The "ZBTB45 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZBTB45 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets